The Role of Cyclin E1(CCNE1) in Hepatocellular Carcinoma Treated with Sorafenib
碩士 === 國立臺灣大學 === 醫學檢驗暨生物技術學研究所 === 100 === Sorafenib is a drug for standard systemic therapy in patients with advanced HCC (hepatocellular carcinoma), and it is also the first drug with survival benefits. Although sorafenib was originally designed as a specific Raf kinase inhibitor, we and other in...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2012
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/77012274372421627568 |